Clinicians sought potential therapeutic options for individuals with poor prognoses in two others; one with T-ALL and CD4/CD8 double negative immunophenotypeand one with infantile B-ALL (2/18, 11.1%). This evidence concerns the gene CD4 and precursor B-cell acute lymphoblastic leukemia.